Zotova Elena, Lyrenäs Louise, de Faire Ulf, Morgenstern Ralf, Gigante Bruna, Bennet Anna M
of Biochemical Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm S-171 77, Sweden.
Coron Artery Dis. 2009 Aug;20(5):322-6. doi: 10.1097/MCA.0b013e32832da06d.
The aim of this study is to investigate the potential role of functional myeloperoxidase (MPO) promoter polymorphisms in the occurrence of myocardial infarction (MI) in the Stockholm Heart Epidemiology Program.
Two MPO promoter polymorphisms, -129G/A and -463G/A, were genotyped in the Stockholm Heart Epidemiology Program population (n = 2774). The -129A allele was associated with a lower risk of MI in women [odds ratio (OR) (95% confidence interval): 0.65 (0.43-0.98), P = 0.03] but not in men [OR: 1.12 (0.86-1.47), P = 0.38]. When women were stratified by age and hormone replacement therapy, the protective effect of the -129A allele was only evident in women younger than 55 years or not receiving hormone replacement therapy. In these two groups, OR (95% confidence interval) for carriers of the -129A allele were 0.34 (0.12-0.92) (P = 0.03) and 0.51 (0.32-0.81) (P = 0.004), respectively. For the -463G/A polymorphism, no associations to MI risk were observed either in women or in men.
The A allele of the MPO -129G/A promoter polymorphism is associated with a reduced MI risk in women.
本研究旨在调查功能性髓过氧化物酶(MPO)启动子多态性在斯德哥尔摩心脏流行病学项目心肌梗死(MI)发生中的潜在作用。
在斯德哥尔摩心脏流行病学项目人群(n = 2774)中对两种MPO启动子多态性,即-129G/A和-463G/A进行基因分型。-129A等位基因与女性MI风险降低相关[比值比(OR)(95%置信区间):0.65(0.43 - 0.98),P = 0.03],但与男性无关[OR:1.12(0.86 - 1.47),P = ;当按年龄和激素替代疗法对女性进行分层时,-129A等位基因的保护作用仅在55岁以下或未接受激素替代疗法的女性中明显。在这两组中,-129A等位基因携带者的OR(95%置信区间)分别为0.34(0.12 - 0.92)(P = 0.03)和0.51(0.(P = 0.004)。对于-463G/A多态性,在女性或男性中均未观察到与MI风险的关联。
MPO -129G/A启动子多态性的A等位基因与女性MI风险降低相关。